Published in Gene Therapy Weekly, July 24th, 1995
Somatic transgenesis can be used to confer endogenous production of proteins that have therapeutic characteristics. One such product, sCD4, is known to efficiently inhibit HIV-1 in vitro. Because of its short half-life in vivo, however, it has impaired long-term clinical trials in patients with AIDS.
T. Valere, Institut Cochin de Genetique Moleculaire, Paris, France, and colleagues used a retroviral vector to introduce cDNA of sCD4 into primary mouse fibroblasts ("Continuous...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.